Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that hypaphorine alters cytoskeletal organization in Eucalyptus globulus root hairs, contributing to reduced root hair elongation by possibly disrupting vesicle delivery needed for growth.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

In this study, researchers developed a dissolvable microneedle patch containing baricitinib for alopecia areata treatment, reporting significantly higher hair growth in mouse models compared to controls, suggesting its potential as an effective, pain-free topical therapy.

Oral JAK inhibitors are safe for alopecia areata, but baricitinib may cause more acne and infections.

This case study reports that a man with severe patch-type alopecia areata initially responded to baricitinib treatment but experienced a relapse despite ongoing therapy.

This study found that 79% of adolescents with moderate-to-severe alopecia areata treated with baricitinib experienced significant scalp hair regrowth, although further research is needed to confirm these results.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This study observed that among UK alopecia areata patients seeking JAK inhibitor treatments before public funding, many sourced medication from abroad due to high costs, with variable response rates and significant reliance on social media for information on accessing treatments.

In this study, gene inactivation in mouse hair follicle stem cells lacking ILK impaired wound healing by reducing their progeny’s contribution to the regenerating epidermis, but did not affect hair follicle regeneration.

This source does not report any results or findings, as no abstract is provided.

This study found that inhibiting PKC-β activity with bisindolylmaleimide reduces pigmentation in the skin and hair of guinea pigs and mice by preventing tyrosinase activation.

Baricitinib helps regrow hair in severe alopecia areata, with results varying by initial hair loss severity and episode duration.

This study evaluated 386 patients with inborn errors of immunity and found that over half exhibited cutaneous, ocular, or hair manifestations, with bacterial skin infections and eczema being particularly prevalent. These findings may aid early diagnosis, especially in pediatric cases.

In this study, patients with severe alopecia areata who were treated with baricitinib 4 mg/day for 48 weeks showed significant improvements in both hair regrowth and nail abnormalities, although the correlation between hair and nail improvement was weak.

In this study, deleting the Igf1 receptor in specific skin cells of mice affected hair follicle cycling but not overall skin health, suggesting Igf1r's role in hair cycle regulation through Bmp-4 activation.

This study found that only a small percentage of alopecia areata patients treated with baricitinib in real-world settings would have met the eligibility criteria used in clinical trials.

In this study, baricitinib treatment over an average of 18.5 months resulted in a 72% reduction in alopecia severity scores among patients aged 65 or older, with mild adverse effects and no severe complications reported.

This case report of an infant with IPEX syndrome highlights the importance of early recognition and treatment, as the patient experienced severe symptoms and succumbed before stem cell transplantation.

This piece describes the American Board of Hair Restoration Surgery's efforts to support and enhance the International Society of Hair Restoration Surgery annual meeting but reports no research findings.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

This study observed that patients with severe alopecia areata treated with baricitinib experienced increases in total cholesterol, LDL-C, and HDL-C, consistent with a JAK inhibitor class effect, but the mean increase was modest and lipid-lowering medication initiation was infrequent.

This study found that imiquimod combined with fish oil in a bigel formulation enhanced antitumor effects and reduced inflammatory side effects in a skin cancer model.

This study suggests that Isaria cicadae Miquel rice fermentation extract may enhance regenerative wound healing of hair follicles in mouse skin through the Hippo pathway mechanism.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This study found that 3-indolebutyric acid (IBA) increased root-hair growth in trifoliate orange by elevating auxin levels, while 2-naphthoxyacetic acid (2-NOA) had the opposite effect, inhibiting root-hair growth.

This thesis presents the development of the Breast Utility Instrument (BUI), a new tool for assessing health-related quality of life specifically in breast cancer patients.

This Italian study observed that one third of patients with 25 to 50% scalp hair loss from alopecia areata still experienced active patchy disease at long-term follow-up, and another third progressed to more severe forms like alopecia totalis or universalis, with limited recovery.